This Perspective discusses the following new study published in PLoS Medicine:Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, et al. (2011) Treatment Outcomes and Cost-Effectiveness of Shifting Management of Stable ARTPatients to Nurses in South Africa: An Observational Cohort. PLoS Med 7(7): e1001055. doi:10.1371/journal.pmed. 1001055Lawrence Long and colleagues report that “down-referring” stable HIV patients from a doctor-managed, hospital-based ART clinic to a nurse-managed primary health facility provides good health outcomes and cost-effective treatment for patients.
Decentralized ART Provision a Necessity
Efforts to scale up antiretroviral therapy (ART) for people living with HIV/AIDS in resource-limited settings began with a clear recognition of the need to adapt the model of care from individualized care to a public health approach [1]. Ten years ago, the main model for ART delivery was the Western model: specialized and individualized, with patients receiving careful clinical monitoring and drug regimens that were frequently altered according to tolerability, emergence of resistance, and patient preference. Such a level of care was clearly beyond the capacity of hospital services in sub-Saharan Africa 10 years ago, and which remain for the most part poorly funded, poorly equipped, understaffed, and overwhelmed.Acknowledging the urgency of scaling up treatment for millions of patients in clinical need, innovative approaches to simplified ART delivery were implemented in parallel with (not subsequent to) formal epidemiological assessments. So, the first randomized trial comparing doctors and nurses in the delivery of ART [2] was published 3 years after such “task shifting” was promoted by the World Health Organization [3]. Whilst trial data were important to validate the task shifting approach, the lack of sufficient numbers of doctors in high-burden countries meant that by the time the evidence was published, hundreds of thousands of patients were already dependent on nurses and other mid-level health workers for their HIV care.New evidence is welcomed. A study published this week in PLoS Medicine by Lawrence Long and colleagues [4] reports the feasibility and benefits of “down-referring” ARTpatients from hospitals to health centers in South Africa, and shows that ART provision at the health centers was beneficial for both patients (better survival and retention in case) and providers (reduced costs). This type of study is important to stimulate donors and program managers to go further in supporting ART provision beyond centralized, hospital-based facilities. That this type of care is urgently needed is supported by a recent survey by Médecins Sans Frontières revealing that less than one-fifth of public health facilities in the Central African Republic, Guinea, Kenya, Mozambique, and Uganda provided ART [5].In common with task shifting, which out of necessity was implemented before formal evidence of efficacy was reported, the decentralized provision of ART beyond the hospital level has been happening for several years in many resource-limited settings, where hospitals are few and distant from patients, out of necessity. In Malawi, patients have received ART at health centers since 2006, with outcomes better than those obtained in the hospital [6]. Reports from South Africa [7] and Lesotho [8] show similarly reassuring outcomes for decentralized care.
Moving ART Provision beyond the Health System
The effectiveness of ART delivery in reducing mortality in resource-limited settings has been established [9], and there is increasing evidence that providing ART earlier will reduce hospitalizations and opportunistic infections [8] and contribute to reducing HIV transmission [10]. But the effectiveness of the health system in delivering ART is questionable, considering the high rates of patient attrition along the treatment cascade from HIV diagnosis to long-term treatment [11]. Given that there are still some 10 million people considered eligible for ART but not receiving it, a strategy of initiating ART treatment for patients in hospitals and then down-referring them to a clinic once they are stable has in many settings already reached its limits.An important question raised by Long et al. 's study, therefore, is how can research help define future HIV programs, rather than validate what is already happening? Few would disagree that the proper role of a hospital is to treat critically illpatients, not to dispense medicines to healthy people. Yet there is little agreement and no policy guidance about how far we can go beyond the health system. The fact that retention in care is consistently reported to be better at decentralized sites [4],[6],[7],[12] indicates the importance of providing care as close as possible to people's homes.We need to go much further. The ambition today is to provide ART to many more people, and much earlier in their infection, over a long-term period. Realizing this ambition will depend on defining models of ART delivery that are minimally intrusive to patient's lives. Several studies have demonstrated the feasibility of home-based [13] and community-based [14] ART management, with positive results. Future research on ART delivery should build on these findings in order to help develop the elements that promote early HIV diagnosis, ensuring rapid enrollment into care, and support continuous adherence to an effective treatment regimen such that HIV care is largely a self-managed chronic disease, with the role of hospitals limited to providing care for a sick minority.
Authors: Ian Sanne; Catherine Orrell; Matthew P Fox; Francesca Conradie; Prudence Ive; Jennifer Zeinecker; Morna Cornell; Christie Heiberg; Charlotte Ingram; Ravindre Panchia; Mohammed Rassool; René Gonin; Wendy Stevens; Handré Truter; Marjorie Dehlinger; Charles van der Horst; James McIntyre; Robin Wood Journal: Lancet Date: 2010-07-03 Impact factor: 79.321
Authors: Marielle Bemelmans; Thomas van den Akker; Nathan Ford; Mit Philips; Rony Zachariah; Anthony Harries; Erik Schouten; Katharina Hermann; Beatrice Mwagomba; Moses Massaquoi Journal: Trop Med Int Health Date: 2010-10-19 Impact factor: 2.622
Authors: Mark A Micek; Kenneth Gimbel-Sherr; Alberto João Baptista; Eduardo Matediana; Pablo Montoya; James Pfeiffer; Armando Melo; Sarah Gimbel-Sherr; Wendy Johnson; Stephen Gloyd Journal: J Acquir Immune Defic Syndr Date: 2009-11-01 Impact factor: 3.731
Authors: Shabbar Jaffar; Barbara Amuron; Susan Foster; Josephine Birungi; Jonathan Levin; Geoffrey Namara; Christine Nabiryo; Nicaise Ndembi; Rosette Kyomuhangi; Alex Opio; Rebecca Bunnell; Jordan W Tappero; Jonathan Mermin; Alex Coutinho; Heiner Grosskurth Journal: Lancet Date: 2009-11-24 Impact factor: 79.321
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Jean B Nachega; Olatunji Adetokunboh; Olalekan A Uthman; Amy W Knowlton; Frederick L Altice; Mauro Schechter; Omar Galárraga; Elvin Geng; Karl Peltzer; Larry W Chang; Gilles Van Cutsem; Shabbar S Jaffar; Nathan Ford; Claude A Mellins; Robert H Remien; Edward J Mills Journal: Curr HIV/AIDS Rep Date: 2016-10 Impact factor: 5.071
Authors: Miguel Angel Luque-Fernandez; Gilles Van Cutsem; Eric Goemaere; Katherine Hilderbrand; Michael Schomaker; Nompumelelo Mantangana; Shaheed Mathee; Vuyiseka Dubula; Nathan Ford; Miguel A Hernán; Andrew Boulle Journal: PLoS One Date: 2013-02-13 Impact factor: 3.240
Authors: Florian J B Scheibe; Peter Waiswa; Daniel Kadobera; Olaf Müller; Anna M Ekström; Malabika Sarker; H W Florian Neuhann Journal: PLoS One Date: 2013-07-23 Impact factor: 3.240
Authors: Ivy Mushamiri; Wintana Belai; Emma Sacks; Becky Genberg; Sundeep Gupta; Henry B Perry Journal: J Glob Health Date: 2021-07-10 Impact factor: 4.413